Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
Praxis Precision Medicines (NASDAQ: PRAX) has successfully closed its upsized initial public offering, selling 11,500,000 shares of common stock at a price of $19.00 per share, raising approximately $218.5 million in gross proceeds. The offering, which included the full exercise of underwriters' options for 1,500,000 additional shares, commenced trading on the Nasdaq Global Select Market on October 16, 2020. All shares were sold by Praxis, with Cowen, Evercore ISI, and Piper Sandler serving as joint book-running managers.
Praxis Precision Medicines (NASDAQ: PRAX) announced the pricing of its upsized IPO, offering 10 million shares at $19.00 each, aiming for gross proceeds of approximately $190 million. The shares will start trading on the Nasdaq on October 16, 2020, with the offering expected to close on October 20, 2020, subject to customary closing conditions. Underwriters include Cowen, Evercore ISI, and Piper Sandler, with an option for an additional 1.5 million shares. The company focuses on developing therapies for central nervous system disorders.